198 related articles for article (PubMed ID: 31257681)
1. Collaboration of MYC and RUNX2 in lymphoma simulates T-cell receptor signaling and attenuates p53 pathway activity.
Hay J; Gilroy K; Huser C; Kilbey A; Mcdonald A; MacCallum A; Holroyd A; Cameron E; Neil JC
J Cell Biochem; 2019 Oct; 120(10):18332-18345. PubMed ID: 31257681
[TBL] [Abstract][Full Text] [Related]
2. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo.
Blyth K; Vaillant F; Hanlon L; Mackay N; Bell M; Jenkins A; Neil JC; Cameron ER
Cancer Res; 2006 Feb; 66(4):2195-201. PubMed ID: 16489021
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic Runx1-Myc axis in p53-deficient thymic lymphoma.
Date Y; Taniuchi I; Ito K
Gene; 2022 Apr; 819():146234. PubMed ID: 35114276
[TBL] [Abstract][Full Text] [Related]
4. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
5. Addiction to Runx1 is partially attenuated by loss of p53 in the Eµ-Myc lymphoma model.
Borland G; Kilbey A; Hay J; Gilroy K; Terry A; Mackay N; Bell M; McDonald A; Mills K; Cameron E; Neil JC
Oncotarget; 2016 Apr; 7(17):22973-87. PubMed ID: 27056890
[TBL] [Abstract][Full Text] [Related]
6. The p53 transcriptional response across tumor types reveals core and senescence-specific signatures modulated by long noncoding RNAs.
Tesfaye E; Martinez-Terroba E; Bendor J; Winkler L; Olivero C; Chen K; Feldser DM; Zamudio JR; Dimitrova N
Proc Natl Acad Sci U S A; 2021 Aug; 118(31):. PubMed ID: 34326251
[TBL] [Abstract][Full Text] [Related]
7. Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging.
Blyth K; Terry A; Mackay N; Vaillant F; Bell M; Cameron ER; Neil JC; Stewart M
Oncogene; 2001 Jan; 20(3):295-302. PubMed ID: 11313958
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
Meng X; Carlson NR; Dong J; Zhang Y
Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
[TBL] [Abstract][Full Text] [Related]
9. Regulatory elements in the immunoglobulin heavy chain gene 3'-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells.
Wang J; Boxer LM
J Biol Chem; 2005 Apr; 280(13):12766-73. PubMed ID: 15687498
[TBL] [Abstract][Full Text] [Related]
10. Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad.
Frenzel A; Labi V; Chmelewskij W; Ploner C; Geley S; Fiegl H; Tzankov A; Villunger A
Blood; 2010 Feb; 115(5):995-1005. PubMed ID: 19965635
[TBL] [Abstract][Full Text] [Related]
11. Targeting SMYD2 inhibits prostate cancer cell growth by regulating c-Myc signaling.
Li J; Wan F; Zhang J; Zheng S; Yang Y; Hong Z; Dai B
Mol Carcinog; 2023 Jul; 62(7):940-950. PubMed ID: 37036190
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Ras, Raf and L-myc but not Bcl-2 family proteins is linked with resistance to TCR-mediated apoptosis and tumorigenesis in thymic lymphomas from TCR transgenic mice.
Kobzdej M; Matuszyk J; Strzadala L
Leuk Res; 2000 Jan; 24(1):33-8. PubMed ID: 10634643
[TBL] [Abstract][Full Text] [Related]
13. Cdk2 suppresses cellular senescence induced by the c-myc oncogene.
Campaner S; Doni M; Hydbring P; Verrecchia A; Bianchi L; Sardella D; Schleker T; Perna D; Tronnersjö S; Murga M; Fernandez-Capetillo O; Barbacid M; Larsson LG; Amati B
Nat Cell Biol; 2010 Jan; 12(1):54-9; sup pp 1-14. PubMed ID: 20010815
[TBL] [Abstract][Full Text] [Related]
14. The glucocorticoid receptor is increased in Atm-/- thymocytes and in Atm-/- thymic lymphoma cells, and its nuclear translocation counteracts c-myc expression.
Yan M; Kuang X; Scofield VL; Shen J; Lynn WS; Wong PK
Steroids; 2007 May; 72(5):415-21. PubMed ID: 17418878
[TBL] [Abstract][Full Text] [Related]
15. Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency.
Zwolinska AK; Heagle Whiting A; Beekman C; Sedivy JM; Marine JC
Oncogene; 2012 Jul; 31(28):3311-21. PubMed ID: 22081066
[TBL] [Abstract][Full Text] [Related]
16. Runx1 Orchestrates Sphingolipid Metabolism and Glucocorticoid Resistance in Lymphomagenesis.
Kilbey A; Terry A; Wotton S; Borland G; Zhang Q; Mackay N; McDonald A; Bell M; Wakelam MJ; Cameron ER; Neil JC
J Cell Biochem; 2017 Jun; 118(6):1432-1441. PubMed ID: 27869314
[TBL] [Abstract][Full Text] [Related]
17. Myc, Cdk2 and cellular senescence: Old players, new game.
Campaner S; Doni M; Verrecchia A; Fagà G; Bianchi L; Amati B
Cell Cycle; 2010 Sep; 9(18):3655-61. PubMed ID: 20818171
[TBL] [Abstract][Full Text] [Related]
18. p53 and p73 in suppression of Myc-driven lymphomagenesis.
Griesmann H; Schlereth K; Krause M; Samans B; Stiewe T
Int J Cancer; 2009 Jan; 124(2):502-6. PubMed ID: 18942718
[TBL] [Abstract][Full Text] [Related]
19. WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma.
Sun Y; Bell JL; Carter D; Gherardi S; Poulos RC; Milazzo G; Wong JW; Al-Awar R; Tee AE; Liu PY; Liu B; Atmadibrata B; Wong M; Trahair T; Zhao Q; Shohet JM; Haupt Y; Schulte JH; Brown PJ; Arrowsmith CH; Vedadi M; MacKenzie KL; Hüttelmaier S; Perini G; Marshall GM; Braithwaite A; Liu T
Cancer Res; 2015 Dec; 75(23):5143-54. PubMed ID: 26471359
[TBL] [Abstract][Full Text] [Related]
20. Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss.
Baudino TA; Maclean KH; Brennan J; Parganas E; Yang C; Aslanian A; Lees JA; Sherr CJ; Roussel MF; Cleveland JL
Mol Cell; 2003 Apr; 11(4):905-14. PubMed ID: 12718877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
